Tai Chi for Diabetes
- Conditions
- Type 2 diabetesMetabolic and Endocrine - Diabetes
- Registration Number
- ACTRN12606000008527
- Lead Sponsor
- Mayne Health
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Type 2 diabetes, diagnosed by doctor. Baseline HbA1c of 7.5 or above.
Exclusion Criteria
Co-morbidity precluding participation in moderate exerciseUnwilling to accept randomisationEnrolled in formal/specific exercise programmes.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HbA1c[Measured at baseline (before randomisation) and after 6 months.];HOMA[Measured at baseline (before randomisation) and after 6 months.];Blood pressure[Measured at baseline (before randomisation) and after 6 months.];Health-related quality of life[Measured at baseline (before randomisation) and after 6 months.]
- Secondary Outcome Measures
Name Time Method Strength[Measured at baseline (before randomisation) and after 6 months.];Body composition (% fat)[Measured at baseline (before randomisation) and after 6 months.];Balance[Measured at baseline (before randomisation) and after 6 months.]
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways does Tai Chi modulate in type 2 diabetes to improve cardiovascular risk factors?
How does Tai Chi compare to aerobic exercise in reducing HbA1c and lipid profiles in type 2 diabetes patients?
Which biomarkers predict cardiovascular improvement in type 2 diabetes patients practicing Tai Chi?
What are the safety profiles and adverse event management strategies for Tai Chi in type 2 diabetes populations?
Are there complementary non-pharmacological interventions with Tai Chi for optimizing metabolic outcomes in type 2 diabetes?